Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 3, 2008, Pages 217-222

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Mugellini, Amedeo ^a   Corradi, Luca ^a   Lazzari, Pierangelo ^a   Preti, Paola ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Atenolol; Atrial fibrillation recurrence; Diabetes mellitus; Hypertension; Valsartan

Indexed keywords

AMIODARONE; AMLODIPINE; ATENOLOL; DISOPYRAMIDE; FLECAINIDE; PROPAFENONE; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; AMLODIPINE; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL FIBRILLATION; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROPAFENONE; PROSPECTIVE STUDIES; RECURRENCE; TETRAZOLES; VALINE;

EID: 41349084427     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318160b42a     Document Type: Article

References (43)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation inadults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-364.
3. Vidaillet H, Granada JF, Chyou PH, et al. A population based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113:365-370.
4. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba Follow-up Study. Am J Med. 1995;98:476-484.
5. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
6. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes mellitus and hypertension in a Swedish community. Diabetes Obes Metab. 2004;6:367-374.
7. Mohaved MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105:315-321.
8. Lip GYH, Varughese GI. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol. 2005;105:319-321.
9. Klem I, Wehinger C, Schneider B, et al. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev. 2003;19:320-328.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-1431.
11. Corley SD, Epstein AE, Di Marco JP, et al. Relationships between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
12. Allessie MA. Atrial electrophysiological remodeling: another vicious circle? J Cardiovasc Electrophysiol. 1998;9:1378-1393.
13. Nattel S, Shiroshita-Takeshita A, Cardin S, et al. Mechanisms of atrial remodelling and clinical relevance. Curr Opin Cardiol. 2005;20:21-25.
14. Van der Berg MP, Crijns HJ, Van Veldhuisen DJ. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1:355-364.
15. Pedersen OD, Bagger H, Keber L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.
16. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insights from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation. 2003;107:2926-2931.
17. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation. 2002;106:331-336.
18. Lindholm LH, Dahlof B, Edelman JM, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet. 2003;362:619-620.
19. Wachtell K, Letho M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention For End-point reduction in hypertension (LIFE) Study. J Am Coll Cardiol. 2005;45:712-719.
20. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-557.
21. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular dysfunction: results from the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004.
22. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47:46-50.
23. Galinier M, Pathak A, Roncalli J. Angiotensin receptor blockers and cardiac rhythm disorders. Arch Mal Coeur Vaiss. 2006;99:745-747.
24. Hansson L, Hedner T, Dahlof B. Prospective, randomizes, open-label, blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press 1992;1:113-114.
25. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2005;27:512-518
26. Hayashi H, Wang C, Miyauchi Y, et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2002;13:801-808.
27. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400-405.
28. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodelling of a different sort. Circulation. 1999;100:87-95
29. Kato T, Yamashita T, Seiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol. 2006;17:890-894.
30. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxyterminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291.
31. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis:results of randomized trial. Circulation. 2004;110:552-557.
32. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy. The Losartan Intervention for End-point reduction in hypertension (LIFE) study. Hypertension. 2002;39:739-743.
33. Malmqvist K, Kahan T, Edner M, et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002;90:1107-1112.
34. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003:115:41-46.
35. Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For End-point reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-1462.
36. Nattel S, Ehrlich JR. Atrial fibrillation. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 4th edition. Philadelphia: Saunders, 2004; 512-521.
37. Doronin SV, Potapova IA, Lu Z, et al. Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization. J Biol Chem 2004;279:48231-48237.
38. Caballero R, Delpon E, Valenzuela C, et al. Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation. 2002;101:1199-1205.
39. Delpon E, Caballero R, Gomez R, et al. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends Pharmacol Sci. 2005;26:155-161.
40. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension. 1998;32:976-982.
41. ++ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia induced atrial remodelling in dogs. Circulation. 1999;100:2191-2197.
42. Li Y, Li W, Xue J, et al. Effects of losartan on acute atrial electrical remodeling. Chin Med J. 2004;117:643-646.
43. Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J. 2000;139:S2-S8.